Statement Of Cash Flows [Abstract]
| Concept |
2023-01-01 to 2023-12-31 |
2022-01-01 to 2022-12-31 |
|---|---|---|
| Statement of cash flows [abstract] | ||
| Cash flows from (used in) operating activities [abstract] | ||
| Adjustments for interest income |
355,000
USD
|
-
USD
|
| Cash flows from (used in) operations before changes in working capital |
5,707,000
USD
|
2,188,000
USD
|
| Adjustments for decrease (increase) in biological assets |
1,142,000
USD
|
2,421,000
USD
|
| Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, inventories |
77,000
USD
|
689,000
USD
|
| Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, property, plant and equipment |
17,000
USD
|
795,000
USD
|
| Adjustments for gains (losses) on change in fair value less costs to sell, biological assets |
2,899,000
USD
|
4,602,000
USD
|
| Adjustments for gain (loss) on disposal of investments in subsidiaries, joint ventures and associates |
926,000
USD
|
9,915,000
USD
|
| Cash flows from (used in) investing activities [abstract] | ||
| Purchase of biological assets |
1,760,000
USD
|
-
USD
|
| Proceeds from disposal of non-current assets or disposal groups classified as held for sale and discontinued operations |
24,000
USD
|
16,000
USD
|
| Proceeds from disposals of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets |
103,000
USD
|
151,000
USD
|